Previous Close | 16.64 |
Open | 16.45 |
Bid | 16.61 x 1200 |
Ask | 16.64 x 1000 |
Day's Range | 16.33 - 16.91 |
52 Week Range | 10.49 - 27.25 |
Volume | |
Avg. Volume | 475,296 |
Market Cap | 1.336B |
Beta (5Y Monthly) | 1.69 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.61 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for NGM
Poster presentation at upcoming ESMO Annual Congress to highlight analysis of subgroup of patients with prostate cancer in NGM120 Phase 1a trialShort-talk presentation at upcoming AACR Special Conference: Pancreatic Cancer to highlight analysis of patients with advanced pancreatic cancer in NGM120 Phase 1b trial SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transfo
One thing we could say about the analysts on NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) - they aren't optimistic...
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -7.27% and 37.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?